Natixis Advisors LLC Cuts Stake in Illumina, Inc. (NASDAQ:ILMN)

Natixis Advisors LLC reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 325,036 shares of the life sciences company’s stock after selling 46,575 shares during the period. Natixis Advisors LLC’s holdings in Illumina were worth $43,435,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its stake in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new stake in Illumina during the 4th quarter worth approximately $32,000. Assetmark Inc. increased its stake in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Illumina during the 4th quarter worth approximately $45,000. Finally, TD Private Client Wealth LLC grew its holdings in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on ILMN shares. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a report on Friday, February 28th. Morgan Stanley lowered their price target on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Barclays reiterated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. Piper Sandler boosted their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Robert W. Baird lowered their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and an average target price of $140.90.

Illumina Stock Up 1.8 %

Shares of NASDAQ:ILMN opened at $85.60 on Monday. The stock has a market cap of $13.56 billion, a P/E ratio of -11.15, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 1-year low of $80.18 and a 1-year high of $156.66. The firm has a fifty day moving average price of $113.52 and a 200 day moving average price of $129.86.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.